Facebook Tracking Image

National Comprehensive Cancer Network

Interactive CME


Educational Events & Programs

 

NCCN Policy Summit:
Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care

 

NCCN POLICY SUMMIT UPDATES > Click here for the press release.

 

OVERVIEW

On September 12, 2019, NCCN hosted a summit entitled, Defining, Measuring, and Applying Quality in an Evolving Health Policy Landscape and the Implications for Cancer Care. The summit presented diverse perspectives related to defining, measuring, and paying for quality as cancer care is inundated with innovative, personalized, and high-cost interventions. Experts in the field discussed the role of outcomes-based oncology quality measures in policy decision-making, including how the patient experience is considered and applied in clinical decision-making. The summit also evaluated how clinical utility and personalized medicine outcomes shape the health care system. These discussions culminated with how the various measures, policies, and regulations ultimately impact patient care.

An article will be published in Journal of the National Comprehensive Cancer Network―JNCCN.

Please check back often for additional updates regarding the summit. If you have any meeting content or agenda questions, please contact Lindsey Bandini, MPH, Quality of Oncology Care Fellow, U.S. and Global Development. For any media questions, please contact Rachel Darwin, P ublic Relations Manager.


SUPPORTERS

Supported by Adaptive Biotechnologies; AmerisourceBergen; an educational donation provided by Amgen; Apobiologix; Astellas; AstraZeneca through its NCCN Corporate Council Membership; Celgene Corporation; Eisai Inc.; EMD Serono; Ferring Pharmaceuticals; Foundation Medicine, Inc.; GSK; HELSINN; Heron; Incyte Corporation; Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson; Kite, a Gilead Company; an independent educational grant from Merck & Co., Inc.; Novartis Oncology; Regeneron Pharmaceuticals Inc; TESARO, A GSK Company; and Verastem Oncology. Sponsored by Boehringer Ingelheim Pharmaceuticals Inc; Bristol-Myers Squibb; Dendreon Pharmaceuticals LLC. This event is sponsored by Lilly Oncology; This activity was made possible by Pharmacyclics, an AbbVie Company.

As of September 4, 2019.


Access the Library of White Papers!

NCCN offers a broad library of white papers from previous summits that may be pertinent to your organization.

View Supporter Opportunities.

NCCN offers organizations various supporter opportunities.